Targeted inhibition of CSF1R signaling has the potential to treat a wide variety of neurodegenerative diseases associated with chronic neuroinflammation such as AD, PD, Huntington’s disease, ALS, multiple sclerosis, and psychiatric disorders. This evidence concerns the gene CSF1R and Parkinson disease.